A spontaneous hematoma reminds columnist Jennifer Lynne of the importance of taking all symptoms and bleeding seriously with hemophilia.

Cutting-edge DNA mapping technology has identified new genetic information that can help researchers decipher more genetic ...

The UK medicines regulator has approved Pfizer’s marstacimab for patients aged 12 years or older with severe haemophilia A or B, offering a new subcutaneous treatment option.

Bengaluru: The country's first human gene therapy trial for haemophilia was conducted through a collaboration between ...

Researchers from the Francis Crick Institute, UCL, Gustave Roussy and Memorial Sloan Kettering Cancer Center (MSK), have ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine marstacimab (Hympavzi) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35 ...

Pfizer’s Hympavzi (marstacimab) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to ...

DelveInsight's "HEMLIBRA Market Size, Forecast, and Market Insight Report" highlights the details around HEMLIBRA, a ...

Many people in Kenya may be living with an undiagnosed rare bleeding disorder known as hemophilia, which may put them at risk ...